Therapy News and Research

RSS

HPTN study results show additional benefits of early ART in HIV clinical outcomes

Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes.

27 Jul 2012

High-dose IL-2 still the most effective treatment for patients with stage IV metastatic melanoma

Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective.

26 Jul 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A. Inc. today announced the filing of a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking approval for a new indication for AMITIZA (lubiprostone) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.

26 Jul 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

Short-course palliative RT shows promise

A 2-day course of three-dimensional radiotherapy delivered in twice-daily fractions up to 18 Gy resulted in no dose-limiting toxicities, and high rates of symptom relief in patient with pelvic cancer, especially those with bleeding, report researchers.

26 Jul 2012

LPL deficiency treatment poised to be first gene therapy in Europe

For the first time, the European Medicines Agency has recommended gene therapy for approval in Europe.

26 Jul 2012

PTSD prevalent in serious mental illness patients

Post-traumatic stress disorder is common among patients with serious mental illnesses, and is associated with an increased risk for suicide attempts, Spanish researchers report.

26 Jul 2012

Congenital long QT syndrome guidelines ‘too restrictive’

Athletes who choose to continue competing after being diagnosed with long QT syndrome have a low rate of LQTS-triggered cardiac events, US researchers report.

26 Jul 2012

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Since its discovery in 1989, hepatitis C virus (HCV) has been recognized as a major cause of chronic liver disease worldwide. The most recent WHO estimate of the prevalence of HCV infection is 2%, representing . about 150 million people. Every year, 3–4 million new people are infected with the hepatitis C virus, of those, approximately 60–80% develop chronic hepatitis, and 30% of them progress to cirrhosis and to end-stage liver disease.

26 Jul 2012

Virginia Hospital Center offers new Calypso System for patients with prostate cancer

Virginia Hospital Center is among the few hospitals along the east coast to offer the new Calypso® System featuring GPS for the Body technology and Beacon electromagnetic transponders for patients with certain types of cancer.

26 Jul 2012

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.

26 Jul 2012

Child who received first stem cell trachea transplant functioning well two years on

The first child stem cell-supported trachea transplant is functioning well two years on, according to an Article published Online First in The Lancet today. The follow-up of the procedure, carried out in 2010 at Great Ormond Street Hospital (GOSH), shows that the new organ has strengthened and does not appear to have induced any signs of rejection. The 13-year-old boy who received the transplant continues to breathe normally, has grown 11 cm in height and has returned to school. He does not require any anti-rejection therapy.

26 Jul 2012

AAQ chemical temporarily restores vision in blind mice

A team of University of California, Berkeley, scientists in collaboration with researchers at the University of Munich and University of Washington in Seattle has discovered a chemical that temporarily restores some vision to blind mice, and is working on an improved compound that may someday allow people with degenerative blindness to see again.

26 Jul 2012

Malaria misdiagnosis: an interview with Dr Toby Leslie

Malaria is caused by a multi-staged parasite which is transmitted by the bite of infected female anopheles mosquitoes. It affects millions of people and kills more than 500,000 people throughout the world every year.

26 Jul 2012

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal.

26 Jul 2012

Diabetic women more likely to report low overall sexual satisfaction

Women with diabetes are just as likely to be interested in, and engage in, sexual activity as non-diabetic women, but they are much more likely to report low overall sexual satisfaction, according to a UCSF study.

26 Jul 2012

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection.

26 Jul 2012

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.

26 Jul 2012

Researchers discover new cause of congenital myopathy

University of Michigan researchers have discovered a new cause of congenital myopathy: a mutation in a previously uncharacterized gene, according to research published this month in the American Journal of Human Genetics.

26 Jul 2012

Therapy News and Research

HPTN study results show additional benefits of early ART in HIV clinical outcomes

High-dose IL-2 still the most effective treatment for patients with stage IV metastatic melanoma

Fusion of FGFR and TACC gene leads to glioblastoma

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Short-course palliative RT shows promise

LPL deficiency treatment poised to be first gene therapy in Europe

PTSD prevalent in serious mental illness patients

Congenital long QT syndrome guidelines ‘too restrictive’

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Virginia Hospital Center offers new Calypso System for patients with prostate cancer

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

Child who received first stem cell trachea transplant functioning well two years on

AAQ chemical temporarily restores vision in blind mice

Malaria misdiagnosis: an interview with Dr Toby Leslie

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Diabetic women more likely to report low overall sexual satisfaction

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

Researchers discover new cause of congenital myopathy

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News